Laloi, L., Billotey, N. C., Dumas, P., Paul, F., Villate, A., Simand, C., Fornecker, L., Puisset, F., Bertoli, S., Simonet, M. B., Laribi, K., Houyou, D., Santagostino, A., Michel, C., Guepin, G. R., Guerineau, E., Tabrizi, R., Hunault, M., Giltat, A., Kaphan, E., Bulabois, C., Cartet, E., Rocher, C., Lachenal, F., Morisset, S., Récher, C., Pigneux, A., Belhabri, A., Michallet, M., & Michallet, A. (2023). retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. Cancer medicine, 12, 7175–7181. http://access.bl.uk/ark:/81055/vdc_100183025045.0x000014